TRAVERSE: A phase 1 multicenter study evaluating the safety and efficacy of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Samer A Srour, MD[1]; Ritesh Kotecha, MD[2]; Brendan Curti, MD[3]; Jad Chahoud, MD[4]; Alexandra Drakaki, MD, PhD[5]; Lily Tang, PhD [6]; Lovely Goyal, PhD[6]; Sacha Prashad, PhD[6]; Victoria Szenes, MS [6]; Sumanta Pal, MD[7]

Samer A. Srour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, United States

[1] The University of Texas MD Anderson Cancer Center, Houston, TX; [2] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; [3] Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; [4] H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; [5] Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA; [6] Allogene Therapeutics, South San Francisco, CA; [7] Comprehensive Cancer Center, City of Hope National Medical Center, Duarte, CA.

TRAVERSE: First-in-Human Trial of Allogeneic Anti-CD70 CAR T Candidate for RCC

AACR American Association for Cancer Research ANNUAL MEETING 2023
APRIL 14-19 • #AACR23

- **Relapsed and refractory RCC represents high unmet need**
  - Large patient population with poor survival outcomes[1-3]
  - Limited effective therapeutic options after failure of immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs)
- **CD70 is a promising target for CAR T therapy**[4]
  - Expressed in up to 80% of RCC; expressed in other hematologic and solid tumors
  - Restricted expression in normal tissue
- **ALLO-316: a novel off-the-shelf CAR T candidate targeting CD70**
  - HLA-unmatched T cell product engineered to express anti-CD70 CAR
  - Double knock-out (TCR and CD52) to reduce GvHD risk and facilitate conditioning with fludarabine, cyclophosphamide, and ALLO-647, an anti-CD52 antibody
  - CD70 CAR designed to avoid fratricide, thereby avoiding disrupting CD70 in CAR T cells
  - Includes CD20 mimotope-based intra-CAR off switch, enabling effective CAR T elimination with rituximab



1. Rao A, et al. *Ann Transl Med.* 2018;6(9):165. 2. Hsieh JJ, et al. *Nat Rev Dis Primers.* 2017;3:17009. 3. Huang JJ, Hsieh JJ. *Kidney Cancer.* 2020;4:121-129. 4. Ruf M, et al. *Clin Cancer Res.* 2015;21(4):889-898.

TRAVERSE: Study Design and Objectives

- Phase 1 multicenter, dose-escalation study, exploring **two conditioning regimens** and **4 cell dose levels** (DLs)

Conditioning Regimen	FCA	FC
Fludarabine (F)	30 mg / m^2 daily x 3	
Cyclophosphamide (C)	300* mg / m^2 daily x 3	
ALLO-647 (A)	10 mg daily x 3	-

*Optional to increase cyclophosphamide to 500mg / m2

Dose Regimen	DL1	DL2	DL3	DL4
Cell Dose (CAR+ T cells)	40 x 10^6	80 x 10^6	120 x 10^6	240 x 10^6

Enrollment in dose escalation is ongoing

Treatment Schema



Key Objectives

- Establish safety and tolerability of ALLO-316
- Determine the recommended cell dose and conditioning regimen
- Evaluate antitumor activity of ALLO-316 in subjects with varying levels of CD70 expression
- Investigate ALLO-316 kinetics with different conditioning regimens

TRAVERSE: Patient Demographics and Disposition

- All patients had advanced or metastatic ccRCC and prior therapy ICI and TKI
- **Median time from enrollment to initiation of conditioning**: 5 days (range: 1–15)
- 95% of enrolled patients (n=19) received ALLO-316
  - DL1 (40 x 10^6): 9 patients
  - DL2 (80 x 10^6): 8 patients
  - DL3 (120 x 10^6): 2 patients
- Median follow-up time: 7.8 months (range: 0.4 –18.1)

Demographic Data at Baseline	Patients who received ALLO-316[a] (n=19)
Age, median (range), yrs	62 (50, 70)
Gender: Male / Female, %	84 / 16
ECOG PS: 0 / 1, %	63 / 37
Disease Stage IV, %	100
Previous Nephrectomy, %	79
Tumor Burden at Baseline, % ≥50 mm, % ≥100 mm, %	 79% 42%
Time Since Original Diagnosis, median (range), months	42.7 (12.1, 216.3)
Lines of Prior Therapy, median (range)	3 (1, 8)
Failed >1 ICI/AI, %	73.7/52.6

[a] Of 20 patients enrolled, the Safety Analysis Set includes 19 patients who underwent conditioning and received ALLO-316; this dataset excludes one patient who received one dose of conditioning but did not receive ALLO-316 because the subject tested positive for COVID-19

Data Extract: March 23, 2023

ALLO-316: Safety and Tolerability

- **Toxicity**
  - The safety profile is overall comparable to what is seen with autologous CAR T
  - One DLT event (Gr 3 type 2 autoimmune hepatitis[a]) in DL2 FCA
  - Manageable low-grade CRS
  - No ICANS or GVHD
  - Two Gr 3 neurotoxicity (syncope and fatigue)
  - One patient had Gr 5 respiratory failure in the setting of COVID-19 infection deemed unrelated to study treatment
  - Infections now managed with enhanced prophylaxis
- **Dose exploration continuing**

TEAEs of Interest[b]	Patients who received ALLO-316 (n=19)	
	All Grades n (%)	Grade 3+ n (%)
Infusion-Related Reaction	1 (5)	0
CRS	11 (58)	1 (5)
ICANS	0	0
GvHD	0	0
Neurotoxicity[c]	13 (68)	2 (11)
Infection[d]	8 (42)	4 (21)
Prolonged Grade 3+ Cytopenia[e]	N/A	3 (16)

[a] DLT initially reported as elevated AST/elevated ALT.
[b] Number of patients with AE occurring from the start of study drug up to subsequent anti-cancer therapy. For patients reporting more than one AE within a preferred term, only one AE with the maximum grade is reported.
[c] Neurotoxicity including ICANS: includes preferred terms (PT) from the Allogene MedDRA Query (AMQ) for Neurologic toxicities including ICANs, a broad search basket of over 200 PTs selected to identify the medical concept. The majority of neurotoxicities are fatigue and headache.
[d] The 4 Gr 3+ infections comprised 2 bacterial (PICC line infection and UTI), 1 fungal (bronchopulmonary aspergillosis) and 1 viral (Gr 5 respiratory failure in setting of COVID-19). At the time of data cut, one additional Gr 3 fungal sinusitis had not yet been recoded as disease progression.
[e] Prolonged Cytopenia at Day 28, includes Grade 3 or above neutropenia, thrombocytopenia, anaemia or pancytopenia which is present at Study Day 28.

Data Extract: March 23, 2023

ALLO-316: Anti-Tumor Activity in CD70+ RCC

AACR American Association for Cancer Research ANNUAL MEETING 2023
APRIL 14-19 • #AACR23

- **Patients evaluable for efficacy (n=18):**
  - ORR = 17%, DCR = 89%
- **Patients with CD70+ RCC (n=10):**
  - 3/10 (30%) achieved PR
  - DCR = 100%
  - Median progression-free survival of 5.0 months
  - Higher Baseline tumor CD70 IHC H-Score correlated with greater tumor reduction

Response Rates[a]	All Patients (n=18[c])	CD70+ Patients (n=10[c])
ORR[a], n (%)	3 (17)	3 (30)
DCR, n (%)	16 (89)	10 (100)



[a] Modified intention-to-treat (mITT) analysis (n=18); DOR values for the 2 confirmed PRs per RECIST 1.1 were 2.9 and 7.0 months; median follow-up time of 8 months; DCR includes initial assessment of SD
[b] H-Score is the weighted CD70 expression on a scale of 0–300; H-score = CD70 intensity x % positivity
[c] Of 19 patients dosed with ALLO-316, 18 had at least 1 tumor assessment

Data Extract: March 23, 2023

ALLO-316: Anti-Tumor Activity in CD70+ RCC

AACR American Association for Cancer Research ANNUAL MEETING 2023
APRIL 14-19 • #AACR23



Data Extract: March 23, 2023

ALLO-316: Durable Disease Control in CD70+ RCC

AACR American Association for Cancer Research ANNUAL MEETING 2023
APRIL 14-19 • #AACR23



*Deepening response from D28 (27% reduction from baseline) to D56 (35% reduction from baseline). Unconfirmed response at M4 with 17% increase from nadir. PD at M6. Follow-up ongoing post re-treatment.

Data Extract: March 23, 2023

TRAVERSE Case Study 1:
Deepening Response After Lowest Tested Cell Dose

AACR American Association for Cancer Research ANNUAL MEETING 2023
APRIL 14-19 • #AACR23

- 68-year-old man with metastatic RCC to the lungs, refractory to multiple ICIs (ipilimumab, nivolumab, and pembrolizumab) and axitinib
- Treated with FCA and ALLO-316 40M CAR+ cells
- Responded with initial partial response at Month 1 that continued to deepen until Month 8, demonstrating durability of response to low dose ALLO-316



TRAVERSE Case Study 2:
Primary Tumor Shrinkage in Patient With Stable Disease

AACR American Association for Cancer Research
ANNUAL MEETING 2023
APRIL 14-19 • #AACR23

- 70-year-old male with RCC metastatic to adrenal and bone, refractory to axitinib and pembrolizumab
- Treated with FCA and 80M CAR+ cells
- Best Overall Response of Stable Disease with 45% decrease in size of primary left kidney tumor



Robust ALLO-316 CAR T Cell Expansion, Persistence and Tumor Trafficking

AACR American Association for Cancer Research
ANNUAL MEETING 2023
APRIL 14-19 • #AACR23

ALLO-316 Expansion After Single-Dose



ALLO-316 Detected in 3 of 4 Available Tumor Aspirates



- High CAR T cell expansion was observed following both conditioning regimens and at relatively low cell doses; in peripheral blood, median peak expansion was 35,000 copies/µg
- High VCN observed in 3 of 4 available tumor aspirates; demonstrates the ability of ALLO-316 to infiltrate the tumor environment

ALLO-316 Eliminates CD70+ Host T Cells, Preventing Allorejection and Supporting Persistence

AACR American Association for Cancer Research ANNUAL MEETING 2023
APRIL 14-19 • #AACR23





- Following ALLO-316 infusion, alloreactive host T cells upregulate CD70 by Day 4
- ALLO-316 expands by Day 10 and eliminates CD70+ host T cells while CD70- host T cells are spared
- Host CD70+ T cells recover as ALLO-316 contracts

Summary: Preliminary Safety and Efficacy of ALLO-316 in Advanced RCC

AACR American Association for Cancer Research
ANNUAL MEETING 2023
APRIL 14-19 • #AACR23

Off-the-shelf CAR T with encouraging anti-tumor activity and no unexpected safety signals

- Treatment initiated with a median of 5 days from enrollment
- Safety profile consistent with autologous CAR T
- Anti-tumor activity in relapsed/refractory advanced CD70+ metastatic RCC
  - 100% disease control and 30% objective response rates in a heavily pretreated population with few therapeutic options
- ALLO-316 depleted alloreactive CD70+ host T cells (“dagger effect”), leading to marked expansion and persistence of allogeneic CAR T cells, even at low cell doses
- Dose escalation ongoing in CD70+ RCC; expansion cohorts planned by the end of 2023 with potential inclusion of additional CD70+ tumors

Thank You!

To our patients, their families and caregivers,

&

our clinical trial investigators and sites

The CD70 ALLO CAR-T program, which utilizes Cellectis technology, is exclusively licensed from Cellectis by Allogene and Allogene holds global development and commercial rights.